Janus Henderson Group PLC grew its stake in Quest Diagnostics Inc (NYSE:DGX) by 24.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,801,477 shares of the medical research company’s stock after buying an additional 349,703 shares during the period. Janus Henderson Group PLC owned 1.32% of Quest Diagnostics worth $168,690,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Parallel Advisors LLC raised its holdings in shares of Quest Diagnostics by 0.9% during the second quarter. Parallel Advisors LLC now owns 1,291 shares of the medical research company’s stock worth $140,000 after purchasing an additional 12 shares during the last quarter. Thrivent Financial For Lutherans raised its holdings in shares of Quest Diagnostics by 2.0% during the second quarter. Thrivent Financial For Lutherans now owns 5,200 shares of the medical research company’s stock worth $578,000 after purchasing an additional 100 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Quest Diagnostics by 3.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,894 shares of the medical research company’s stock worth $434,000 after purchasing an additional 131 shares during the last quarter. D.A. Davidson & CO. raised its holdings in shares of Quest Diagnostics by 1.2% during the second quarter. D.A. Davidson & CO. now owns 12,788 shares of the medical research company’s stock worth $1,421,000 after purchasing an additional 147 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in shares of Quest Diagnostics by 1.0% during the second quarter. Marshall Wace LLP now owns 17,659 shares of the medical research company’s stock worth $1,960,000 after purchasing an additional 177 shares during the last quarter. 89.20% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently issued reports on the stock. BidaskClub raised shares of Quest Diagnostics from a “sell” rating to a “hold” rating in a report on Tuesday, August 15th. Canaccord Genuity reissued a “buy” rating and set a $118.00 target price on shares of Quest Diagnostics in a report on Wednesday, September 13th. Craig Hallum reissued a “hold” rating and set a $100.00 target price (down previously from $110.00) on shares of Quest Diagnostics in a report on Tuesday, October 17th. SunTrust Banks set a $105.00 target price on shares of Quest Diagnostics and gave the stock a “hold” rating in a report on Sunday, October 15th. Finally, Mizuho set a $103.00 target price on shares of Quest Diagnostics and gave the stock a “buy” rating in a report on Thursday, October 19th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company’s stock. Quest Diagnostics presently has a consensus rating of “Hold” and an average target price of $106.28.

Quest Diagnostics Inc (NYSE:DGX) opened at $97.10 on Tuesday. Quest Diagnostics Inc has a fifty-two week low of $90.10 and a fifty-two week high of $112.96. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.37. The firm has a market cap of $13,230.58, a price-to-earnings ratio of 17.40, a price-to-earnings-growth ratio of 2.02 and a beta of 0.60.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Thursday, October 19th. The medical research company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. The company had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.92 billion. During the same quarter in the previous year, the company earned $1.37 earnings per share. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. equities research analysts expect that Quest Diagnostics Inc will post 5.65 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Stockholders of record on Tuesday, January 9th will be given a $0.45 dividend. The ex-dividend date of this dividend is Monday, January 8th. This represents a $1.80 annualized dividend and a dividend yield of 1.85%. Quest Diagnostics’s dividend payout ratio (DPR) is 37.74%.

ILLEGAL ACTIVITY NOTICE: “Quest Diagnostics Inc (DGX) Shares Bought by Janus Henderson Group PLC” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/quest-diagnostics-inc-dgx-shares-bought-by-janus-henderson-group-plc/1759212.html.

Quest Diagnostics Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.